FMO5 and Myocardial fibrosis: Previous studies revealed that the pharmacological mechanism of dantonic against AMI involved anti-platelet aggregation, reducing the overload of calcium and circulating adhesion molecules, ameliorating myocardial fibrosis, protecting against microcirculatory disturbances, inhibiting NADPH oxidase, and modulating the perturbed energy metabolism (Xin et al., 2013; Yang et al., 2013; Zou et al., 2015).